Across TCGA pan-cancer cohorts, CD55 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD55 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD55 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD55 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CD55 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.312	0.505	<.001	77	view →
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	18	view →
LUAD	DFS	Median	All	0.864	0.936	.017	6	view →
GBM	OS	Quartile	All	0.952	0.724	.011	5	view →
LSCC	OS	Quartile	II,III,IV	0.554	0.934	.025	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CD55 tumor-vs-normal RNA expression · all CD55 data types